| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 88 | 2023 | 3444 | 7.710 |
Why?
|
| Genomics | 67 | 2023 | 5720 | 5.130 |
Why?
|
| Alzheimer Disease | 147 | 2023 | 8037 | 5.050 |
Why?
|
| Genetic Counseling | 30 | 2022 | 600 | 3.550 |
Why?
|
| Disclosure | 25 | 2022 | 736 | 3.500 |
Why?
|
| Genome, Human | 31 | 2023 | 4420 | 2.960 |
Why?
|
| Genetic Predisposition to Disease | 89 | 2023 | 17446 | 2.960 |
Why?
|
| Apolipoproteins E | 36 | 2018 | 1438 | 2.700 |
Why?
|
| Incidental Findings | 11 | 2018 | 689 | 2.300 |
Why?
|
| Neonatal Screening | 17 | 2023 | 591 | 2.250 |
Why?
|
| Apolipoprotein E4 | 23 | 2016 | 668 | 1.810 |
Why?
|
| Sequence Analysis, DNA | 18 | 2019 | 4803 | 1.580 |
Why?
|
| Biological Specimen Banks | 7 | 2021 | 711 | 1.470 |
Why?
|
| Genetics, Medical | 9 | 2023 | 338 | 1.390 |
Why?
|
| Genetic Privacy | 5 | 2018 | 60 | 1.380 |
Why?
|
| Genetic Diseases, Inborn | 5 | 2017 | 587 | 1.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 21 | 2022 | 3923 | 1.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2020 | 3597 | 1.250 |
Why?
|
| Disease | 4 | 2021 | 680 | 1.250 |
Why?
|
| Parents | 19 | 2023 | 3407 | 1.240 |
Why?
|
| Family | 18 | 2021 | 3147 | 1.210 |
Why?
|
| Genetic Variation | 30 | 2021 | 6544 | 1.140 |
Why?
|
| Truth Disclosure | 8 | 2019 | 436 | 1.050 |
Why?
|
| Rare Diseases | 4 | 2023 | 553 | 1.040 |
Why?
|
| Aminophylline | 2 | 2015 | 40 | 1.020 |
Why?
|
| Genetic Research | 10 | 2021 | 174 | 1.000 |
Why?
|
| Sequence Analysis | 2 | 2015 | 256 | 0.950 |
Why?
|
| Chondroitinsulfatases | 1 | 2023 | 16 | 0.910 |
Why?
|
| Health Literacy | 2 | 2021 | 414 | 0.880 |
Why?
|
| Perception | 8 | 2018 | 1198 | 0.880 |
Why?
|
| Humans | 356 | 2023 | 744343 | 0.860 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2019 | 15519 | 0.800 |
Why?
|
| Attitude to Health | 12 | 2019 | 2052 | 0.800 |
Why?
|
| Genotype | 43 | 2023 | 12951 | 0.790 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 535 | 0.790 |
Why?
|
| Research Subjects | 6 | 2018 | 239 | 0.750 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2015 | 339 | 0.720 |
Why?
|
| Insurance, Long-Term Care | 3 | 2011 | 18 | 0.720 |
Why?
|
| Aged, 80 and over | 99 | 2023 | 57776 | 0.710 |
Why?
|
| Male | 217 | 2023 | 350118 | 0.710 |
Why?
|
| Biomedical Research | 12 | 2021 | 3309 | 0.690 |
Why?
|
| Aged | 154 | 2023 | 163280 | 0.690 |
Why?
|
| Female | 216 | 2023 | 380194 | 0.680 |
Why?
|
| Cognition Disorders | 24 | 2016 | 4043 | 0.680 |
Why?
|
| Penetrance | 3 | 2023 | 381 | 0.650 |
Why?
|
| Motivation | 15 | 2022 | 1971 | 0.650 |
Why?
|
| Prenatal Diagnosis | 2 | 2023 | 1236 | 0.650 |
Why?
|
| Risk Assessment | 36 | 2023 | 23338 | 0.620 |
Why?
|
| Decision Making | 16 | 2022 | 3887 | 0.620 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2021 | 379 | 0.610 |
Why?
|
| Middle Aged | 130 | 2023 | 213383 | 0.600 |
Why?
|
| Policy | 1 | 2021 | 508 | 0.600 |
Why?
|
| Neuropsychological Tests | 34 | 2014 | 6993 | 0.590 |
Why?
|
| Adult | 110 | 2023 | 214055 | 0.590 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 602 | 0.580 |
Why?
|
| Multifactorial Inheritance | 3 | 2021 | 1194 | 0.550 |
Why?
|
| Genome-Wide Association Study | 30 | 2022 | 12261 | 0.550 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 3843 | 0.530 |
Why?
|
| Adoption | 1 | 2016 | 97 | 0.530 |
Why?
|
| Research | 2 | 2021 | 1999 | 0.530 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 1695 | 0.530 |
Why?
|
| Ethics, Medical | 1 | 2021 | 792 | 0.520 |
Why?
|
| Primary Health Care | 11 | 2023 | 4558 | 0.510 |
Why?
|
| Telephone | 2 | 2020 | 617 | 0.510 |
Why?
|
| Prion Diseases | 1 | 2016 | 88 | 0.500 |
Why?
|
| Insurance Selection Bias | 1 | 2015 | 67 | 0.500 |
Why?
|
| Public Health | 5 | 2022 | 2603 | 0.500 |
Why?
|
| Cognition | 19 | 2020 | 6770 | 0.490 |
Why?
|
| Health Behavior | 11 | 2018 | 2636 | 0.490 |
Why?
|
| Prions | 1 | 2016 | 180 | 0.480 |
Why?
|
| Antigens, Human Platelet | 3 | 2019 | 43 | 0.460 |
Why?
|
| Memory | 4 | 2016 | 2174 | 0.460 |
Why?
|
| Consumer Advocacy | 1 | 2014 | 81 | 0.450 |
Why?
|
| Insurance | 1 | 2015 | 111 | 0.450 |
Why?
|
| United States Food and Drug Administration | 5 | 2023 | 1584 | 0.440 |
Why?
|
| Hippocampus | 11 | 2017 | 3675 | 0.440 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 500 | 0.430 |
Why?
|
| Amyloid beta-Peptides | 11 | 2023 | 3587 | 0.420 |
Why?
|
| Blood Group Antigens | 3 | 2019 | 180 | 0.420 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 121 | 0.420 |
Why?
|
| Informed Consent | 8 | 2021 | 995 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2023 | 9959 | 0.410 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3610 | 0.410 |
Why?
|
| Population Surveillance | 5 | 2020 | 2616 | 0.410 |
Why?
|
| Disease Progression | 27 | 2023 | 13284 | 0.410 |
Why?
|
| Etomidate | 1 | 2014 | 190 | 0.400 |
Why?
|
| Research Report | 1 | 2015 | 355 | 0.400 |
Why?
|
| Infant, Newborn | 26 | 2023 | 25625 | 0.400 |
Why?
|
| Mental Recall | 4 | 2012 | 1205 | 0.390 |
Why?
|
| Risk Factors | 54 | 2023 | 72290 | 0.390 |
Why?
|
| Patient Preference | 7 | 2018 | 890 | 0.390 |
Why?
|
| Patient Education as Topic | 8 | 2018 | 2278 | 0.390 |
Why?
|
| Mass Screening | 6 | 2022 | 5255 | 0.380 |
Why?
|
| Ethylene Glycols | 4 | 2018 | 156 | 0.380 |
Why?
|
| Physicians | 6 | 2023 | 4567 | 0.380 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 13989 | 0.380 |
Why?
|
| Family Health | 4 | 2010 | 1282 | 0.380 |
Why?
|
| Anesthetics, Intravenous | 1 | 2014 | 417 | 0.380 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 241 | 0.370 |
Why?
|
| Flurbiprofen | 1 | 2009 | 21 | 0.370 |
Why?
|
| Attitude | 4 | 2023 | 776 | 0.360 |
Why?
|
| Mutation | 12 | 2023 | 29786 | 0.360 |
Why?
|
| Health Communication | 1 | 2013 | 214 | 0.350 |
Why?
|
| United States | 44 | 2023 | 69872 | 0.350 |
Why?
|
| Academies and Institutes | 1 | 2012 | 317 | 0.350 |
Why?
|
| Information Dissemination | 5 | 2018 | 1099 | 0.350 |
Why?
|
| Brain | 27 | 2019 | 26385 | 0.350 |
Why?
|
| Prescription Drugs | 1 | 2016 | 595 | 0.340 |
Why?
|
| Pedigree | 10 | 2015 | 4644 | 0.340 |
Why?
|
| Aging | 11 | 2015 | 8664 | 0.340 |
Why?
|
| Comprehension | 6 | 2018 | 610 | 0.340 |
Why?
|
| Self Disclosure | 1 | 2009 | 251 | 0.330 |
Why?
|
| Age of Onset | 15 | 2019 | 3271 | 0.320 |
Why?
|
| Presenilins | 1 | 2008 | 54 | 0.320 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2019 | 107 | 0.320 |
Why?
|
| Communication | 10 | 2021 | 3749 | 0.320 |
Why?
|
| Postpartum Period | 1 | 2014 | 1086 | 0.320 |
Why?
|
| Employment | 1 | 2015 | 1132 | 0.310 |
Why?
|
| Human Genome Project | 1 | 2008 | 193 | 0.310 |
Why?
|
| Ethylene Glycol | 1 | 2007 | 29 | 0.310 |
Why?
|
| Genetic Loci | 8 | 2020 | 2575 | 0.310 |
Why?
|
| Government | 1 | 2008 | 165 | 0.310 |
Why?
|
| Private Sector | 2 | 2011 | 392 | 0.300 |
Why?
|
| Young Adult | 31 | 2021 | 56430 | 0.300 |
Why?
|
| Risk | 11 | 2016 | 9687 | 0.300 |
Why?
|
| Civil Rights | 1 | 2008 | 132 | 0.300 |
Why?
|
| Methanol | 1 | 2007 | 85 | 0.300 |
Why?
|
| Antidotes | 1 | 2007 | 138 | 0.290 |
Why?
|
| Aniline Compounds | 4 | 2018 | 986 | 0.290 |
Why?
|
| Medical History Taking | 4 | 2018 | 783 | 0.280 |
Why?
|
| Dementia | 9 | 2012 | 2518 | 0.280 |
Why?
|
| Pharmacogenetics | 7 | 2023 | 675 | 0.280 |
Why?
|
| Solvents | 1 | 2007 | 302 | 0.280 |
Why?
|
| Genome | 4 | 2022 | 1808 | 0.280 |
Why?
|
| Fluorine Radioisotopes | 2 | 2018 | 442 | 0.270 |
Why?
|
| Computational Biology | 7 | 2019 | 3521 | 0.270 |
Why?
|
| Adaptation, Psychological | 4 | 2013 | 2576 | 0.270 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 584 | 0.270 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 1504 | 0.270 |
Why?
|
| Neoplasms | 6 | 2022 | 21683 | 0.270 |
Why?
|
| Pyrazoles | 4 | 2011 | 1972 | 0.270 |
Why?
|
| Intubation, Intratracheal | 1 | 2014 | 1364 | 0.270 |
Why?
|
| Wounds and Injuries | 2 | 2019 | 2400 | 0.270 |
Why?
|
| Health Care Costs | 5 | 2019 | 3209 | 0.260 |
Why?
|
| Personal Satisfaction | 5 | 2018 | 643 | 0.260 |
Why?
|
| Physicians, Primary Care | 3 | 2018 | 591 | 0.260 |
Why?
|
| Geriatric Assessment | 9 | 2013 | 1372 | 0.260 |
Why?
|
| Adult Children | 1 | 2005 | 100 | 0.250 |
Why?
|
| Physician-Patient Relations | 6 | 2018 | 3229 | 0.250 |
Why?
|
| tau Proteins | 7 | 2023 | 1868 | 0.250 |
Why?
|
| Naproxen | 3 | 2011 | 99 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2023 | 3255 | 0.240 |
Why?
|
| Prejudice | 1 | 2008 | 570 | 0.240 |
Why?
|
| Research Design | 7 | 2014 | 5987 | 0.230 |
Why?
|
| Amino Acid Transport System y+L | 1 | 2023 | 17 | 0.230 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 15165 | 0.230 |
Why?
|
| Phenotype | 15 | 2023 | 16365 | 0.230 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2019 | 554 | 0.220 |
Why?
|
| Fabry Disease | 1 | 2023 | 90 | 0.220 |
Why?
|
| Bradycardia | 2 | 2015 | 307 | 0.220 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2023 | 99 | 0.210 |
Why?
|
| Nova Scotia | 3 | 2019 | 34 | 0.210 |
Why?
|
| Apolipoprotein E3 | 4 | 2013 | 97 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 3 | 2021 | 977 | 0.210 |
Why?
|
| Duty to Recontact | 1 | 2021 | 20 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Professional-Patient Relations | 3 | 2017 | 737 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 2703 | 0.210 |
Why?
|
| Politics | 1 | 2008 | 791 | 0.210 |
Why?
|
| Arthritis, Rheumatoid | 4 | 2018 | 3712 | 0.200 |
Why?
|
| National Human Genome Research Institute (U.S.) | 3 | 2016 | 23 | 0.200 |
Why?
|
| Antiporters | 1 | 2023 | 277 | 0.200 |
Why?
|
| Health Education | 3 | 2018 | 1056 | 0.200 |
Why?
|
| Affect | 4 | 2013 | 1476 | 0.200 |
Why?
|
| Stress, Psychological | 7 | 2019 | 4245 | 0.200 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2023 | 440 | 0.200 |
Why?
|
| Mental Status Schedule | 7 | 2011 | 321 | 0.200 |
Why?
|
| Laboratories | 2 | 2016 | 463 | 0.190 |
Why?
|
| Membrane Transport Proteins | 4 | 2015 | 1028 | 0.190 |
Why?
|
| Access to Information | 2 | 2017 | 320 | 0.190 |
Why?
|
| MNSs Blood-Group System | 1 | 2020 | 8 | 0.190 |
Why?
|
| Data Collection | 9 | 2014 | 3341 | 0.190 |
Why?
|
| Clinical Trials as Topic | 8 | 2018 | 7913 | 0.190 |
Why?
|
| Cohort Studies | 24 | 2021 | 40561 | 0.190 |
Why?
|
| Gastritis | 1 | 2022 | 196 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 7279 | 0.180 |
Why?
|
| HLA-DQ Antigens | 1 | 2020 | 210 | 0.180 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 19905 | 0.180 |
Why?
|
| Educational Status | 9 | 2015 | 2540 | 0.180 |
Why?
|
| HLA-A Antigens | 1 | 2020 | 231 | 0.180 |
Why?
|
| Amnesia | 2 | 2015 | 248 | 0.180 |
Why?
|
| Fluid Therapy | 2 | 2016 | 593 | 0.180 |
Why?
|
| Proxy | 2 | 2016 | 144 | 0.180 |
Why?
|
| Uncertainty | 4 | 2019 | 734 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 241 | 0.180 |
Why?
|
| Population Groups | 2 | 2022 | 209 | 0.180 |
Why?
|
| Clinical Medicine | 1 | 2021 | 147 | 0.170 |
Why?
|
| Executive Function | 2 | 2016 | 1364 | 0.170 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 6773 | 0.170 |
Why?
|
| Child | 24 | 2022 | 77709 | 0.170 |
Why?
|
| HLA-B Antigens | 1 | 2020 | 353 | 0.170 |
Why?
|
| Databases as Topic | 2 | 2019 | 475 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5319 | 0.170 |
Why?
|
| Confidentiality | 4 | 2019 | 612 | 0.170 |
Why?
|
| Primary Prevention | 1 | 2006 | 1167 | 0.170 |
Why?
|
| Workflow | 2 | 2022 | 847 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2011 | 2282 | 0.170 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 2356 | 0.170 |
Why?
|
| Biotinidase | 1 | 2018 | 19 | 0.170 |
Why?
|
| Personal Autonomy | 3 | 2019 | 298 | 0.170 |
Why?
|
| Insurance Coverage | 2 | 2021 | 1901 | 0.170 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 645 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 3798 | 0.160 |
Why?
|
| Traumatology | 1 | 2019 | 88 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 849 | 0.160 |
Why?
|
| Ambulances | 1 | 2019 | 95 | 0.160 |
Why?
|
| Aryldialkylphosphatase | 2 | 2010 | 63 | 0.160 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 15540 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 2916 | 0.160 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2019 | 768 | 0.160 |
Why?
|
| Age Factors | 18 | 2019 | 18370 | 0.160 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2018 | 65 | 0.160 |
Why?
|
| Atrophy | 8 | 2015 | 1583 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2023 | 11725 | 0.160 |
Why?
|
| Life Style | 6 | 2016 | 3835 | 0.160 |
Why?
|
| Transportation of Patients | 1 | 2019 | 185 | 0.160 |
Why?
|
| LDL-Receptor Related Proteins | 2 | 2008 | 115 | 0.150 |
Why?
|
| Research Personnel | 2 | 2013 | 573 | 0.150 |
Why?
|
| Case-Control Studies | 17 | 2019 | 21746 | 0.150 |
Why?
|
| Patient Satisfaction | 4 | 2018 | 3396 | 0.150 |
Why?
|
| Genome, Mitochondrial | 1 | 2018 | 71 | 0.150 |
Why?
|
| Forms and Records Control | 1 | 2018 | 160 | 0.150 |
Why?
|
| Shock, Septic | 2 | 2016 | 775 | 0.150 |
Why?
|
| Cerebral Cortex | 4 | 2020 | 5708 | 0.150 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 618 | 0.150 |
Why?
|
| Emotions | 4 | 2019 | 2661 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2023 | 824 | 0.150 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 128 | 0.150 |
Why?
|
| Germ Cells | 1 | 2021 | 631 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3297 | 0.150 |
Why?
|
| Adolescent | 24 | 2020 | 85781 | 0.150 |
Why?
|
| Trauma Centers | 2 | 2019 | 890 | 0.150 |
Why?
|
| Multigene Family | 3 | 2011 | 1102 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 459 | 0.140 |
Why?
|
| Activities of Daily Living | 4 | 2012 | 2418 | 0.140 |
Why?
|
| Health Personnel | 5 | 2023 | 3218 | 0.140 |
Why?
|
| Attention | 2 | 2010 | 2400 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 340 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 12245 | 0.140 |
Why?
|
| Peptide Fragments | 4 | 2017 | 5097 | 0.140 |
Why?
|
| Follow-Up Studies | 14 | 2016 | 39050 | 0.140 |
Why?
|
| Metagenomics | 1 | 2019 | 428 | 0.140 |
Why?
|
| Cardiomyopathies | 3 | 2019 | 1912 | 0.140 |
Why?
|
| Retinitis Pigmentosa | 1 | 2020 | 386 | 0.140 |
Why?
|
| Concept Formation | 2 | 2015 | 158 | 0.140 |
Why?
|
| Software | 6 | 2019 | 4443 | 0.140 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 4251 | 0.140 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2015 | 5 | 0.140 |
Why?
|
| Newfoundland and Labrador | 2 | 2010 | 12 | 0.140 |
Why?
|
| Sex Factors | 12 | 2019 | 10397 | 0.140 |
Why?
|
| Homozygote | 3 | 2015 | 1785 | 0.140 |
Why?
|
| Heterozygote | 7 | 2019 | 2804 | 0.140 |
Why?
|
| Fetus | 1 | 2023 | 1880 | 0.140 |
Why?
|
| Anxiety | 7 | 2019 | 4297 | 0.130 |
Why?
|
| Positron-Emission Tomography | 4 | 2018 | 6234 | 0.130 |
Why?
|
| Alleles | 9 | 2018 | 6933 | 0.130 |
Why?
|
| Medical Informatics | 2 | 2014 | 745 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2018 | 367 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 1997 | 719 | 0.130 |
Why?
|
| Health | 1 | 2019 | 394 | 0.130 |
Why?
|
| Prospective Studies | 13 | 2022 | 53288 | 0.130 |
Why?
|
| Internationality | 1 | 2021 | 1003 | 0.130 |
Why?
|
| Logistic Models | 9 | 2019 | 13408 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1265 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2020 | 694 | 0.130 |
Why?
|
| Sulfonamides | 3 | 2011 | 1938 | 0.130 |
Why?
|
| Depression | 8 | 2021 | 7766 | 0.130 |
Why?
|
| Pancreatitis | 1 | 2022 | 1092 | 0.130 |
Why?
|
| Gene Frequency | 6 | 2017 | 3588 | 0.130 |
Why?
|
| Erythrocytes | 3 | 2019 | 2455 | 0.130 |
Why?
|
| Amyloid | 2 | 2021 | 795 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 224 | 0.120 |
Why?
|
| Behavioral Medicine | 1 | 1995 | 50 | 0.120 |
Why?
|
| Predictive Value of Tests | 13 | 2017 | 15076 | 0.120 |
Why?
|
| Neurology | 2 | 2010 | 763 | 0.120 |
Why?
|
| Regression Analysis | 7 | 2013 | 6459 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 1504 | 0.120 |
Why?
|
| Learning | 3 | 2010 | 1713 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 5 | 2021 | 5391 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 742 | 0.120 |
Why?
|
| Early Diagnosis | 3 | 2015 | 1184 | 0.120 |
Why?
|
| Exons | 1 | 2020 | 2437 | 0.120 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 6487 | 0.120 |
Why?
|
| Health Care Surveys | 4 | 2018 | 2453 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 1164 | 0.120 |
Why?
|
| Genes, Dominant | 1 | 2016 | 880 | 0.120 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 113 | 0.120 |
Why?
|
| Military Personnel | 2 | 2020 | 1133 | 0.110 |
Why?
|
| Butyrylcholinesterase | 1 | 2013 | 22 | 0.110 |
Why?
|
| Isoxazoles | 1 | 1995 | 216 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 560 | 0.110 |
Why?
|
| Accidents, Traffic | 1 | 2019 | 819 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1420 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1994 | 326 | 0.110 |
Why?
|
| Psychometrics | 2 | 2021 | 3002 | 0.110 |
Why?
|
| Science | 1 | 2016 | 241 | 0.110 |
Why?
|
| Botulinum Toxins | 1 | 1995 | 191 | 0.110 |
Why?
|
| Random Allocation | 2 | 2010 | 2429 | 0.110 |
Why?
|
| Organ Size | 5 | 2020 | 2252 | 0.110 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1405 | 0.110 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2012 | 30 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3022 | 0.110 |
Why?
|
| Trypsinogen | 1 | 2012 | 86 | 0.110 |
Why?
|
| Presenilin-1 | 1 | 2016 | 635 | 0.110 |
Why?
|
| Diagnostic Imaging | 4 | 2012 | 3507 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 3537 | 0.110 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2012 | 238 | 0.110 |
Why?
|
| Immunity | 1 | 2019 | 1012 | 0.110 |
Why?
|
| Odds Ratio | 7 | 2017 | 9849 | 0.110 |
Why?
|
| Chromosome Mapping | 5 | 2021 | 4740 | 0.110 |
Why?
|
| Public Policy | 1 | 2017 | 572 | 0.110 |
Why?
|
| Genes, BRCA1 | 2 | 2014 | 781 | 0.110 |
Why?
|
| Twins, Dizygotic | 1 | 2013 | 236 | 0.110 |
Why?
|
| Health Resources | 1 | 2019 | 911 | 0.110 |
Why?
|
| Calcineurin | 1 | 2013 | 226 | 0.110 |
Why?
|
| Radionuclide Imaging | 5 | 2016 | 2031 | 0.110 |
Why?
|
| Gene Deletion | 1 | 2020 | 2751 | 0.100 |
Why?
|
| Georgia | 4 | 2013 | 186 | 0.100 |
Why?
|
| Valproic Acid | 1 | 1995 | 445 | 0.100 |
Why?
|
| Claudins | 1 | 2012 | 111 | 0.100 |
Why?
|
| Poly T | 1 | 2011 | 5 | 0.100 |
Why?
|
| Blood Preservation | 1 | 2012 | 177 | 0.100 |
Why?
|
| Trypsin | 1 | 2012 | 511 | 0.100 |
Why?
|
| Speech Perception | 1 | 1996 | 489 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 156 | 0.100 |
Why?
|
| Siblings | 3 | 2019 | 854 | 0.100 |
Why?
|
| Interviews as Topic | 3 | 2013 | 2539 | 0.100 |
Why?
|
| Memory Disorders | 4 | 2014 | 1184 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 417 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2019 | 2716 | 0.100 |
Why?
|
| Probability | 3 | 2016 | 2505 | 0.100 |
Why?
|
| Resuscitation | 1 | 2016 | 658 | 0.100 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 20 | 0.100 |
Why?
|
| Cephalometry | 2 | 2010 | 382 | 0.100 |
Why?
|
| Dystonia | 1 | 1995 | 363 | 0.100 |
Why?
|
| Twins, Monozygotic | 1 | 2013 | 458 | 0.100 |
Why?
|
| Age Distribution | 4 | 2011 | 2902 | 0.100 |
Why?
|
| Counseling | 2 | 2020 | 1523 | 0.100 |
Why?
|
| Memantine | 1 | 2012 | 100 | 0.100 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2011 | 200 | 0.100 |
Why?
|
| Depressive Disorder | 2 | 2007 | 3748 | 0.100 |
Why?
|
| Polymorphism, Genetic | 4 | 2009 | 4328 | 0.100 |
Why?
|
| Databases, Bibliographic | 3 | 2016 | 128 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2020 | 35421 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 440 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 246 | 0.100 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2015 | 1121 | 0.100 |
Why?
|
| New York City | 5 | 2012 | 710 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 197 | 0.100 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 1423 | 0.100 |
Why?
|
| Caregivers | 3 | 2013 | 2094 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2011 | 106 | 0.090 |
Why?
|
| Medical Errors | 1 | 2019 | 1297 | 0.090 |
Why?
|
| Plaque, Amyloid | 2 | 2013 | 729 | 0.090 |
Why?
|
| DNA | 2 | 2021 | 7301 | 0.090 |
Why?
|
| Pyrrolidines | 1 | 1992 | 342 | 0.090 |
Why?
|
| Independent Living | 2 | 2011 | 568 | 0.090 |
Why?
|
| Urban Population | 2 | 2009 | 2021 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 3086 | 0.090 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1708 | 0.090 |
Why?
|
| Galactosemias | 1 | 2011 | 125 | 0.090 |
Why?
|
| Ethics Committees, Research | 1 | 2012 | 194 | 0.090 |
Why?
|
| Pilot Projects | 8 | 2018 | 8324 | 0.090 |
Why?
|
| Hospitalization | 5 | 2019 | 10262 | 0.090 |
Why?
|
| Assisted Living Facilities | 1 | 2010 | 25 | 0.090 |
Why?
|
| Founder Effect | 1 | 2010 | 189 | 0.090 |
Why?
|
| Waste Disposal, Fluid | 1 | 2009 | 30 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2005 | 5102 | 0.090 |
Why?
|
| Influenza, Human | 2 | 2012 | 1479 | 0.090 |
Why?
|
| Pregnancy | 3 | 2023 | 29144 | 0.090 |
Why?
|
| Patient-Centered Care | 3 | 2016 | 1439 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 294 | 0.090 |
Why?
|
| Technology Transfer | 1 | 2009 | 44 | 0.090 |
Why?
|
| Personality | 1 | 2013 | 552 | 0.090 |
Why?
|
| Canada | 4 | 2019 | 2065 | 0.090 |
Why?
|
| Acetylcholinesterase | 1 | 1989 | 153 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 449 | 0.090 |
Why?
|
| Linear Models | 5 | 2013 | 5952 | 0.090 |
Why?
|
| Water Purification | 1 | 2009 | 48 | 0.090 |
Why?
|
| Chromatin | 1 | 2021 | 2934 | 0.090 |
Why?
|
| Publications | 1 | 2012 | 195 | 0.090 |
Why?
|
| Patient Selection | 4 | 2018 | 4215 | 0.090 |
Why?
|
| Soil Pollutants | 1 | 2009 | 71 | 0.080 |
Why?
|
| Registries | 3 | 2019 | 8089 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2020 | 2063 | 0.080 |
Why?
|
| Microglia | 1 | 2017 | 1266 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 950 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2011 | 676 | 0.080 |
Why?
|
| Genetic Linkage | 1 | 1994 | 2421 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2013 | 6038 | 0.080 |
Why?
|
| Databases, Genetic | 4 | 2018 | 1783 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2012 | 981 | 0.080 |
Why?
|
| Life Change Events | 1 | 2013 | 938 | 0.080 |
Why?
|
| Trail Making Test | 1 | 2008 | 57 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 326 | 0.080 |
Why?
|
| Washington | 1 | 2008 | 313 | 0.080 |
Why?
|
| Infant | 7 | 2021 | 35136 | 0.080 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2010 | 231 | 0.080 |
Why?
|
| Culture | 1 | 2012 | 633 | 0.080 |
Why?
|
| Organizational Objectives | 1 | 2010 | 438 | 0.080 |
Why?
|
| Piperidines | 2 | 1999 | 1602 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2020 | 10252 | 0.080 |
Why?
|
| Lipids | 1 | 2019 | 3305 | 0.080 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 372 | 0.080 |
Why?
|
| Prealbumin | 1 | 2009 | 210 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 3508 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2020 | 4397 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 426 | 0.070 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 269 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2007 | 119 | 0.070 |
Why?
|
| Family Relations | 1 | 2009 | 321 | 0.070 |
Why?
|
| Linkage Disequilibrium | 4 | 2017 | 1997 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2012 | 544 | 0.070 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 684 | 0.070 |
Why?
|
| Drug Industry | 1 | 2013 | 746 | 0.070 |
Why?
|
| Emergency Medicine | 1 | 2016 | 1207 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2008 | 2634 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2011 | 6365 | 0.070 |
Why?
|
| Orientation | 2 | 2006 | 327 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 1995 | 1076 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2011 | 12026 | 0.070 |
Why?
|
| Massachusetts | 2 | 2017 | 8663 | 0.070 |
Why?
|
| Endocrine Disruptors | 1 | 2009 | 237 | 0.070 |
Why?
|
| Algorithms | 6 | 2018 | 13881 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 3768 | 0.070 |
Why?
|
| Cross-Cultural Comparison | 2 | 2006 | 651 | 0.070 |
Why?
|
| Poisoning | 1 | 2007 | 249 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 1125 | 0.070 |
Why?
|
| Benzodiazepines | 1 | 2012 | 1101 | 0.070 |
Why?
|
| Seizures | 2 | 2009 | 2859 | 0.070 |
Why?
|
| Water Pollutants, Chemical | 1 | 2009 | 311 | 0.070 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 293 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2019 | 1014 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 5853 | 0.070 |
Why?
|
| Mutation, Missense | 2 | 2015 | 2564 | 0.070 |
Why?
|
| Prostatic Neoplasms | 4 | 2023 | 11124 | 0.070 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1989 | 403 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2017 | 2958 | 0.060 |
Why?
|
| Behavior | 1 | 2008 | 561 | 0.060 |
Why?
|
| Weight Loss | 1 | 2016 | 2622 | 0.060 |
Why?
|
| Mental Processes | 1 | 2006 | 249 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 1364 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1519 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2012 | 1670 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1758 | 0.060 |
Why?
|
| Intention | 2 | 2018 | 341 | 0.060 |
Why?
|
| Haplotypes | 3 | 2019 | 2779 | 0.060 |
Why?
|
| Social Stigma | 1 | 2011 | 701 | 0.060 |
Why?
|
| Head | 1 | 2010 | 880 | 0.060 |
Why?
|
| Arabs | 1 | 2006 | 178 | 0.060 |
Why?
|
| Demography | 3 | 2017 | 1656 | 0.060 |
Why?
|
| Individuality | 1 | 2006 | 307 | 0.060 |
Why?
|
| Utah | 3 | 2011 | 126 | 0.060 |
Why?
|
| Community Health Services | 1 | 2010 | 650 | 0.060 |
Why?
|
| Reading | 1 | 2008 | 558 | 0.060 |
Why?
|
| Muscular Diseases | 2 | 2020 | 556 | 0.060 |
Why?
|
| Fatigue | 1 | 2011 | 1531 | 0.060 |
Why?
|
| Inservice Training | 2 | 2019 | 392 | 0.060 |
Why?
|
| Publishing | 1 | 2011 | 833 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 29063 | 0.060 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 748 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 544 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 3 | 2015 | 1677 | 0.060 |
Why?
|
| Altruism | 1 | 2005 | 204 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2011 | 1367 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 1107 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2015 | 3023 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 4644 | 0.060 |
Why?
|
| Critical Care | 1 | 2016 | 2647 | 0.060 |
Why?
|
| Health Status | 3 | 2013 | 4034 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 689 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 875 | 0.060 |
Why?
|
| Smoking | 3 | 2016 | 8987 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2013 | 1470 | 0.060 |
Why?
|
| Physician's Role | 1 | 2010 | 943 | 0.060 |
Why?
|
| Time Factors | 8 | 2019 | 40075 | 0.060 |
Why?
|
| Medical Records | 1 | 2008 | 1413 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2569 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 494 | 0.050 |
Why?
|
| Obesity | 2 | 2016 | 12745 | 0.050 |
Why?
|
| Office Visits | 2 | 2017 | 598 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 1240 | 0.050 |
Why?
|
| Reference Values | 5 | 2008 | 4982 | 0.050 |
Why?
|
| Child of Impaired Parents | 1 | 2006 | 455 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3528 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2010 | 1036 | 0.050 |
Why?
|
| Sclerosis | 2 | 2014 | 213 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2014 | 2025 | 0.050 |
Why?
|
| Visual Perception | 2 | 2012 | 1420 | 0.050 |
Why?
|
| Parent-Child Relations | 2 | 2021 | 747 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2010 | 1158 | 0.050 |
Why?
|
| Personal Health Services | 2 | 2013 | 25 | 0.050 |
Why?
|
| Italy | 2 | 2019 | 832 | 0.050 |
Why?
|
| Sodium Chloride | 2 | 2016 | 625 | 0.050 |
Why?
|
| Tissue Donors | 2 | 2022 | 2240 | 0.050 |
Why?
|
| Ethics, Research | 2 | 2015 | 191 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 2861 | 0.050 |
Why?
|
| Diet | 2 | 2017 | 7939 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 2 | 2014 | 528 | 0.050 |
Why?
|
| Boston | 4 | 2020 | 9313 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2023 | 77449 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 941 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 14722 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 5867 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2016 | 6077 | 0.050 |
Why?
|
| Ethanol | 1 | 2007 | 1342 | 0.050 |
Why?
|
| Graft Survival | 2 | 2022 | 3737 | 0.050 |
Why?
|
| Community Health Planning | 2 | 2012 | 165 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2014 | 3679 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 1257 | 0.050 |
Why?
|
| Exercise | 1 | 2017 | 5615 | 0.050 |
Why?
|
| Length of Stay | 1 | 2014 | 6309 | 0.050 |
Why?
|
| Nootropic Agents | 2 | 2015 | 160 | 0.050 |
Why?
|
| Veterans | 1 | 2014 | 2519 | 0.050 |
Why?
|
| Simvastatin | 1 | 2023 | 360 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2007 | 1106 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2011 | 4026 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 2043 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 780 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 1772 | 0.050 |
Why?
|
| Hospitals, Pediatric | 3 | 2014 | 1775 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 5137 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2838 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 1901 | 0.040 |
Why?
|
| Craniocerebral Trauma | 2 | 2003 | 482 | 0.040 |
Why?
|
| Confusion | 2 | 2012 | 275 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2009 | 1859 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2021 | 7729 | 0.040 |
Why?
|
| Australia | 1 | 2022 | 1170 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 407 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1359 | 0.040 |
Why?
|
| Drowning | 1 | 2019 | 27 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2021 | 275 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7799 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 2 | 2015 | 439 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2017 | 738 | 0.040 |
Why?
|
| Asphyxia | 1 | 2019 | 57 | 0.040 |
Why?
|
| Spouses | 2 | 2013 | 286 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2020 | 741 | 0.040 |
Why?
|
| Cause of Death | 1 | 2009 | 3584 | 0.040 |
Why?
|
| Insurance, Health | 2 | 2008 | 2494 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 177 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2002 | 1005 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 3057 | 0.040 |
Why?
|
| Duty to Warn | 1 | 2018 | 30 | 0.040 |
Why?
|
| Arctic Regions | 1 | 1998 | 25 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 341 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3743 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2019 | 41006 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2021 | 375 | 0.040 |
Why?
|
| Muscles | 1 | 2023 | 1614 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 1203 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1786 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2015 | 7880 | 0.040 |
Why?
|
| Models, Genetic | 4 | 2013 | 3494 | 0.040 |
Why?
|
| Internet | 3 | 2016 | 3064 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3703 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2019 | 129 | 0.040 |
Why?
|
| Fires | 1 | 2019 | 173 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 20822 | 0.040 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 263 | 0.040 |
Why?
|
| Health Policy | 1 | 2010 | 2661 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2013 | 6600 | 0.040 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 7785 | 0.040 |
Why?
|
| Models, Psychological | 2 | 2015 | 811 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2017 | 91 | 0.040 |
Why?
|
| Friends | 1 | 2018 | 154 | 0.040 |
Why?
|
| Genomic Structural Variation | 1 | 2017 | 64 | 0.040 |
Why?
|
| Plasma Substitutes | 1 | 2016 | 57 | 0.040 |
Why?
|
| Hospitals | 2 | 2023 | 3952 | 0.040 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2017 | 76 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 135 | 0.040 |
Why?
|
| Parenting | 1 | 2022 | 679 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2017 | 234 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 4266 | 0.040 |
Why?
|
| Classification | 1 | 2017 | 129 | 0.040 |
Why?
|
| Tropicamide | 1 | 1996 | 23 | 0.040 |
Why?
|
| Medicaid | 1 | 2010 | 2736 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 2018 | 246 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2022 | 1381 | 0.030 |
Why?
|
| Colloids | 1 | 2016 | 136 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 329 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2010 | 4286 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2016 | 119 | 0.030 |
Why?
|
| Cardiology | 2 | 2018 | 1668 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 1996 | 91 | 0.030 |
Why?
|
| Prevalence | 4 | 2018 | 15226 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 367 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2016 | 209 | 0.030 |
Why?
|
| Indiana | 1 | 2015 | 92 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 344 | 0.030 |
Why?
|
| Epilepsy | 1 | 2011 | 3310 | 0.030 |
Why?
|
| Placebo Effect | 1 | 1999 | 502 | 0.030 |
Why?
|
| Mediator Complex | 1 | 2015 | 109 | 0.030 |
Why?
|
| Chicago | 1 | 2015 | 240 | 0.030 |
Why?
|
| Pupil | 1 | 1996 | 149 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1995 | 111 | 0.030 |
Why?
|
| Comorbidity | 4 | 2016 | 10388 | 0.030 |
Why?
|
| Brain Mapping | 3 | 2020 | 6669 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13102 | 0.030 |
Why?
|
| Genetics | 1 | 2015 | 112 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3251 | 0.030 |
Why?
|
| Neck Muscles | 1 | 1995 | 104 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 2 | 2015 | 1061 | 0.030 |
Why?
|
| Amino Acids | 1 | 2020 | 1736 | 0.030 |
Why?
|
| Phenytoin | 1 | 1995 | 197 | 0.030 |
Why?
|
| Parkinson Disease | 2 | 2020 | 2775 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 551 | 0.030 |
Why?
|
| Phenylketonurias | 1 | 2015 | 122 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1788 | 0.030 |
Why?
|
| Tape Recording | 1 | 2013 | 76 | 0.030 |
Why?
|
| Incidence | 5 | 2011 | 20947 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2019 | 1850 | 0.030 |
Why?
|
| Putamen | 1 | 2015 | 291 | 0.030 |
Why?
|
| Qualitative Research | 2 | 2017 | 2682 | 0.030 |
Why?
|
| Social Class | 1 | 2003 | 1999 | 0.030 |
Why?
|
| Acetamides | 1 | 2015 | 249 | 0.030 |
Why?
|
| Income | 1 | 2022 | 1913 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2018 | 907 | 0.030 |
Why?
|
| Program Development | 2 | 2010 | 1316 | 0.030 |
Why?
|
| Albumins | 1 | 2016 | 569 | 0.030 |
Why?
|
| Caudate Nucleus | 1 | 2015 | 393 | 0.030 |
Why?
|
| Adenomatous Polyps | 1 | 1994 | 107 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 465 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2012 | 25043 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2011 | 969 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2011 | 2971 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 105 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 641 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2839 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 204 | 0.030 |
Why?
|
| Government Regulation | 1 | 2017 | 522 | 0.030 |
Why?
|
| Chromosomes | 1 | 2016 | 596 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2012 | 80 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2015 | 2585 | 0.030 |
Why?
|
| Risperidone | 1 | 1995 | 383 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2014 | 250 | 0.030 |
Why?
|
| Binding Sites | 1 | 2021 | 6114 | 0.030 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 195 | 0.030 |
Why?
|
| Overweight | 2 | 2014 | 2371 | 0.030 |
Why?
|
| Quality of Life | 1 | 2013 | 12804 | 0.030 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 144 | 0.030 |
Why?
|
| Social Marketing | 1 | 2011 | 52 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 1345 | 0.030 |
Why?
|
| Proportional Hazards Models | 4 | 2011 | 12354 | 0.030 |
Why?
|
| Patients | 1 | 2018 | 900 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 981 | 0.030 |
Why?
|
| Cholesterol | 1 | 2020 | 2917 | 0.020 |
Why?
|
| Acute Disease | 1 | 2022 | 7149 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 655 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 1086 | 0.020 |
Why?
|
| Apolipoprotein E2 | 1 | 2011 | 127 | 0.020 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2011 | 68 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 5751 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2012 | 184 | 0.020 |
Why?
|
| Problem Solving | 1 | 1994 | 440 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 2015 | 1092 | 0.020 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 2046 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2019 | 1062 | 0.020 |
Why?
|
| Education | 1 | 2014 | 543 | 0.020 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2010 | 24 | 0.020 |
Why?
|
| Mothers | 1 | 2021 | 2165 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2011 | 2297 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 302 | 0.020 |
Why?
|
| Americas | 1 | 2010 | 111 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1889 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2013 | 1030 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 780 | 0.020 |
Why?
|
| Skull | 1 | 2015 | 813 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2005 | 9146 | 0.020 |
Why?
|
| Myocardial Infarction | 3 | 2008 | 11727 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2011 | 166 | 0.020 |
Why?
|
| Observation | 1 | 2012 | 312 | 0.020 |
Why?
|
| Poaceae | 1 | 2009 | 25 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 163 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2015 | 1125 | 0.020 |
Why?
|
| Judgment | 1 | 2012 | 281 | 0.020 |
Why?
|
| Critical Illness | 1 | 2022 | 2670 | 0.020 |
Why?
|
| Biodegradation, Environmental | 1 | 2009 | 219 | 0.020 |
Why?
|
| Oral Health | 1 | 2014 | 472 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3129 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2017 | 2263 | 0.020 |
Why?
|
| Authorship | 1 | 2011 | 271 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 1813 | 0.020 |
Why?
|
| Autopsy | 1 | 2012 | 1020 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1989 | 719 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 840 | 0.020 |
Why?
|
| Greece | 1 | 2009 | 344 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 812 | 0.020 |
Why?
|
| Religion | 1 | 2011 | 356 | 0.020 |
Why?
|
| Health Services Needs and Demand | 2 | 2006 | 1411 | 0.020 |
Why?
|
| Coronary Artery Bypass | 2 | 2008 | 2289 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 2148 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 845 | 0.020 |
Why?
|
| Telomere | 1 | 1994 | 910 | 0.020 |
Why?
|
| Placebos | 1 | 1992 | 1676 | 0.020 |
Why?
|
| Nerve Net | 1 | 2010 | 2174 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 2017 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 571 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2010 | 499 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1462 | 0.020 |
Why?
|
| Marriage | 1 | 2009 | 339 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 1252 | 0.020 |
Why?
|
| Protease Nexins | 1 | 2007 | 40 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2018 | 2508 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2010 | 348 | 0.020 |
Why?
|
| Memory, Short-Term | 1 | 1994 | 975 | 0.020 |
Why?
|
| Rural Population | 1 | 1998 | 2210 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1994 | 1406 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 1321 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2938 | 0.020 |
Why?
|
| Germany | 1 | 2009 | 862 | 0.020 |
Why?
|
| Patient Participation | 1 | 2016 | 1457 | 0.020 |
Why?
|
| Denmark | 1 | 2009 | 738 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 2715 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2015 | 1177 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1792 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2010 | 550 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 9648 | 0.020 |
Why?
|
| Folic Acid | 1 | 2013 | 1300 | 0.020 |
Why?
|
| Commerce | 1 | 2011 | 592 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2013 | 980 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15295 | 0.020 |
Why?
|
| Motor Activity | 1 | 2016 | 2714 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1996 | 1622 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2016 | 6196 | 0.020 |
Why?
|
| Heart | 1 | 2019 | 4467 | 0.020 |
Why?
|
| Celiac Disease | 1 | 2013 | 785 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 12797 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 9981 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13815 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2007 | 371 | 0.020 |
Why?
|
| Selection Bias | 1 | 2007 | 371 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2019 | 5317 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 365 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2006 | 363 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 3658 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2016 | 2071 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2012 | 896 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2008 | 545 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 377 | 0.010 |
Why?
|
| Introns | 1 | 2007 | 991 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2017 | 5021 | 0.010 |
Why?
|
| Endosomes | 1 | 2007 | 520 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2010 | 1534 | 0.010 |
Why?
|
| Israel | 1 | 2006 | 796 | 0.010 |
Why?
|
| ROC Curve | 1 | 2012 | 3527 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 12959 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1070 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4462 | 0.010 |
Why?
|
| Visual Cortex | 1 | 2012 | 1149 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2593 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2825 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 2007 | 977 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1420 | 0.010 |
Why?
|
| Autistic Disorder | 1 | 2013 | 1185 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1861 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 3617 | 0.010 |
Why?
|
| Brain Infarction | 1 | 2005 | 299 | 0.010 |
Why?
|
| Health Surveys | 1 | 2013 | 4037 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8554 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 789 | 0.010 |
Why?
|
| Models, Biological | 2 | 2010 | 9583 | 0.010 |
Why?
|
| Walking | 1 | 2010 | 1180 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2886 | 0.010 |
Why?
|
| RNA | 1 | 2012 | 2749 | 0.010 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 5034 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 2690 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4838 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2007 | 2008 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2011 | 5078 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
| Social Support | 1 | 2011 | 2118 | 0.010 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 7659 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 1791 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2016 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2011 | 2050 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9438 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2618 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2752 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 2009 | 1471 | 0.010 |
Why?
|
| Curriculum | 1 | 2014 | 3605 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4468 | 0.010 |
Why?
|
| Aphasia, Broca | 1 | 1980 | 50 | 0.010 |
Why?
|
| Pediatrics | 1 | 2015 | 3475 | 0.010 |
Why?
|
| Crohn Disease | 1 | 2013 | 2303 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1827 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 2645 | 0.010 |
Why?
|
| Western World | 1 | 1999 | 27 | 0.010 |
Why?
|
| Self Report | 1 | 2011 | 3558 | 0.010 |
Why?
|
| Ginkgo biloba | 1 | 1999 | 26 | 0.010 |
Why?
|
| Causality | 1 | 2006 | 1275 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2005 | 957 | 0.010 |
Why?
|
| Health Promotion | 1 | 2011 | 2205 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6171 | 0.010 |
Why?
|
| Indans | 1 | 1999 | 96 | 0.010 |
Why?
|
| Aphasia | 1 | 1980 | 179 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 167 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 9727 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4687 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 16689 | 0.010 |
Why?
|
| Asia | 1 | 1999 | 610 | 0.010 |
Why?
|
| Mortality | 1 | 2009 | 2864 | 0.010 |
Why?
|
| Fear | 1 | 2006 | 1440 | 0.010 |
Why?
|
| Poverty | 1 | 2009 | 2660 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2866 | 0.010 |
Why?
|
| Phytotherapy | 1 | 1999 | 298 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3327 | 0.010 |
Why?
|
| Serial Learning | 1 | 1996 | 45 | 0.010 |
Why?
|
| Tacrine | 1 | 1996 | 5 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3282 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1782 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 1999 | 486 | 0.010 |
Why?
|
| Ophthalmic Solutions | 1 | 1996 | 317 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1995 | 5788 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8949 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 3752 | 0.010 |
Why?
|
| Verbal Learning | 1 | 1996 | 467 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 12788 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 15997 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 12072 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 63114 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 5655 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 3966 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 168757 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 8480 | 0.000 |
Why?
|
| Speech Disorders | 1 | 1980 | 189 | 0.000 |
Why?
|
| Cerebral Infarction | 1 | 1980 | 1011 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1980 | 2290 | 0.000 |
Why?
|